Santaris Pharma A/S® is pioneering a new era of antisense therapeutics leveraging our Locked Nucleic Acid (LNA) chemistry platform and tissue targeting expertise. We are developing a diverse pipeline of drug candidates that act selectively on disease-related RNAs to provide patients with novel treatments for both rare and common diseases. Our leadership in innovation and passion for the future of RNA therapeutics have attracted multiple large-scale partnerships and yielded exciting and unique LNA-based drugs.